Meeting
2019 ASCO Annual Meeting
A global phase III multicenter, randomized, double-arm, open label trial of ASP-1929 photoimmunotherapy versus physician’s choice standard of care for the treatment of patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
Authors
Merrill A. Biel
Rakuten Aspyrian Inc., San Diego, CA
Merrill A. Biel , Ann M. Gillenwater , David M. Cognetti , Jennifer Maria Johnson , Athanassios Argiris , Makoto Tahara
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT03769506
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS6094)
DOI
10.1200/JCO.2019.37.15_suppl.TPS6094
Abstract #
TPS6094
Poster Bd #
80b
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
First Author: Lisa F. Licitra
Poster
2019 ASCO Annual Meeting
Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.
First Author: Kevin J. Harrington
Poster
2019 ASCO Annual Meeting
Results of a phase 2a, multicenter, open-label, study of RM-1929 photoimmunotherapy (PIT) in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
First Author: David M. Cognetti
Poster
2018 ASCO Annual Meeting
Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040.
First Author: Ezra E.W. Cohen